Tracking Brain Biomarkers and Renormalization Associated with Antidepressant Transcranial Magnetic Stimulation Therapy

Date Added
April 4th, 2023
PRO Number
Pro00127417
Researcher
Andrew Manett

List of Studies


Keywords
Brain, Depression
Summary

The purpose of this study is to use magnetic resonance imaging (MRI) to take images of a participant's brain, and then apply an investigational way of processing the image, called Individualized Network-based Single-frame Coactivation Pattern Estimation ("INSCAPE") to measure participant's brain activity. This method uses a computer program to understand which parts of the brain communicate with each other and creates a map of the brain areas that are connected.

Participants being recruited in this study will include people planning to receive Transcranial Magnetic Stimulation ("TMS") for Major Depressive Disorder ("MDD"). Healthy participants are also being recruited. Images taken of depressed participants' brains will be compared to images of non-depressed participants' brains. Participation in this study will require three visits in which you will undergo MRI scans. The interval between each visits is about 3 weeks. Depressed participants will also complete mood assessments at several different intervals while they are receiving TMS for depression.

During each visit, MRI scans will require about 30 minutes of time in total. During the MRI scan, participants will need to stay still, relax, and keep eyes open in the scanner.

Institution
MUSC
Recruitment Contact
Andrew Manett
843-792-5716
manett@musc.edu

Transcranial Magnetic Stimulation for MCI: A Phase II Dose-Ranging Study

Date Added
March 21st, 2023
PRO Number
Pro00127160
Researcher
Andreana Benitez

List of Studies


Keywords
Aging, Alzheimers, Depression, Memory Loss
Summary

This is a Phase II research study to determine dosing of non-invasive brain stimulation for patients with Mild Cognitive Impairment (MCI) and depression. The brain stimulation treatment used in this study is called repetitive transcranial magnetic stimulation (rTMS). rTMS is a Food and Drug Administration (FDA)-approved treatment for depression. The goal of the study is to see if brain stimulation can be used for MCI patients to improve memory, thinking, and mood, and what dose of stimulation works best.

The study uses a form of rTMS called intermittent theta burst rTMS (accelerated iTBS). This treatment has not been FDA-approved for MCI patients. This double-blind study requires 11 study visits over the course of six months.

Institution
MUSC
Recruitment Contact
Katrina Madden
843-792-9186
maddenka@musc.edu

Synchronized cervical or transcranial auricular Vagus Nerve Stimulation (taVNS) with prefrontal repetitive transcranial magnetic stimulation (rTMS) for treatment resistant depression (TRD)

Date Added
January 3rd, 2023
PRO Number
Pro00125468
Researcher
Mark George

List of Studies


Keywords
Depression
Summary

The purpose of the research is to test out a combined treatment for depression where we stimulate a nerve in the ear while at the same time stimulating the brain with magnets. These treatments are called transcutaneous (through the skin) auricular (ear) vagus nerve stimulation (taVNS) and transcranial (through the skull) magnetic stimulation (TMS). For patients who already have a cervical VNS device, we will not change their treatment and will use this in place of the taVNS. We think this combined method might treat depressive symptoms better than either alone. This study is in person at the Institute of Psychiatry in downtown Charleston on the MUSC campus. First, patients will have a screening session and then will have 6 treatment days total where they will receive either VNS treatment alone, TMS treatment alone, or both at the same time. The treatment they start with will be randomized, and they will have 2 treatment days of each combination.

Institution
MUSC
Recruitment Contact
Noah Vieira
843 2222889
vieira@musc.edu

PCORI 1: Improving Maternal Mental Health & Substance Use Disorder Screening and Treatment

Date Added
November 1st, 2022
PRO Number
Pro00123833
Researcher
Constance Guille

List of Studies


Keywords
Depression, Mental Health, Obstetrics and Gynecology, Post Partum Depression, Pregnancy, Psychiatry, Substance Use, Women's Health
Summary

The purpose of the study is to compare a text message based mental health and substance use screening and referral to treatment program, called Listening to Women and Pregnant and Postpartum People (LTWP), to standard of care in-person mental health and substance use screening to look at rates of treatment attendance and retention in treatment. Participation would involve completing online surveys. You may be eligible to participate if you are age 18-45 years, are pregnant and entering prenatal care in one of MUSC's OB clinics, and attended a prenatal appointment at an MUSC clinic.

Institution
MUSC
Recruitment Contact
Edie Douglas
843-792-5958
douglaed@musc.edu

PCORI 1: Improving Maternal Mental Health & Substance Use Disorder Screening and Treatment

Date Added
November 1st, 2022
PRO Number
Pro00123833
Researcher
Constance Guille

List of Studies


Keywords
Depression, Mental Health, Obstetrics and Gynecology, Post Partum Depression, Pregnancy, Psychiatry, Substance Use, Women's Health
Summary

The purpose of the study is to compare a text message based mental health and substance use screening and referral to treatment program, called Listening to Women and Pregnant and Postpartum People (LTWP), to standard of care in-person mental health and substance use screening to look at rates of treatment attendance and retention in treatment. Participation would involve completing online surveys. You may be eligible to participate if you are age 18-45 years, are pregnant and entering prenatal care in one of MUSC's OB clinics, and attended a prenatal appointment at an MUSC clinic.

Institution
MUSC Health Florence Medical Center
Recruitment Contact
Edie Douglas
843-792-5958
douglaed@musc.edu

PCORI 1: Improving Maternal Mental Health & Substance Use Disorder Screening and Treatment

Date Added
November 1st, 2022
PRO Number
Pro00123833
Researcher
Constance Guille

List of Studies


Keywords
Depression, Mental Health, Obstetrics and Gynecology, Post Partum Depression, Pregnancy, Psychiatry, Substance Use, Women's Health
Summary

The purpose of the study is to compare a text message based mental health and substance use screening and referral to treatment program, called Listening to Women and Pregnant and Postpartum People (LTWP), to standard of care in-person mental health and substance use screening to look at rates of treatment attendance and retention in treatment. Participation would involve completing online surveys. You may be eligible to participate if you are age 18-45 years, are pregnant and entering prenatal care in one of MUSC's OB clinics, and attended a prenatal appointment at an MUSC clinic.

Institution
MUSC Health Lancaster Medical Center
Recruitment Contact
Edie Douglas
843-792-5958
douglaed@musc.edu

Evaluating a novel method to determine the rTMS dose needed for treating depression after spinal cord injury--Phase 2

Date Added
October 4th, 2022
PRO Number
Pro00122278
Researcher
Catherine VanDerwerker

List of Studies


Keywords
Depression, Spinal Cord
Summary

Depression is a leading cause of disability worldwide and is more commonly seen in individuals post-spinal cord injury (SCI) than in the general population. Depression post-SCI impacts an individual's quality of life and recovery. It has been reported that among people with an SCI, those without depression live longer than those with depression. Thus, depression must be treated appropriately. Repetitive transcranial magnetic stimulation (rTMS) is an FDA-approved treatment for depression, but dosing is based on a motor response in the thumb. Over half of individuals with SCI have some degree of arm or hand impairment, so these individuals might not be eligible for rTMS, or they may receive the wrong dose. This study proposes a pilot clinical trial in individuals with depression post-SCI to assess the anti-depressant effect of a novel way to dose rTMS that does not require a motor response. By gaining a better understanding of the application of rTMS for depression post-SCI, we aim to advance the rehabilitative care of those with SCI.

Institution
MUSC
Recruitment Contact
Catherine VanDerwerker
843-792-5047
vanderwe@musc.edu

Developing a Novel Cognitive-Behavioral Intervention for Psychosocial Rehabilitation in Chronic Stroke

Date Added
June 6th, 2022
PRO Number
Pro00118778
Researcher
Lisa McTeague

List of Studies


Keywords
Anxiety, Depression, Stress Disorders, Stroke Recovery
Summary

The purpose of this study is to identify domains in which stroke suvivors may have struggled since experiencing a stroke. These include things like emotional, family and work function. This study entails an interview and questionnaires that ask about functioning in these areas.

The longer-term goal of this work is to identify areas these areas so that we can develop a psychotherapy that could be helpful for individuals recovering from and living with the aftermath of stroke.

Institution
MUSC
Recruitment Contact
Lisa McTeague
843-792-8274
lisa.mcteague@va.gov

Testing a Scalable Model of Care to Improve Patients' Access to Mental Health Services after Traumatic Injury

Date Added
May 3rd, 2022
PRO Number
Pro00112776
Researcher
Kenneth Ruggiero

List of Studies


Keywords
Depression, Mental Health
Summary

Each year, roughly 600,000 patients served in U.S. trauma centers develop posttraumatic stress disorder or depression after traumatic injury, but few receive mental health follow-up care. The Trauma Resilience and Recovery Program is a sustainable, stepped-care model that has addressed the mental health needs of over 8,000 patients in four Level I-II trauma centers and is being adopted by 8 additional trauma centers in the Carolinas. This study will examine the effectiveness and implementation of TRRP with a diverse sample of 350 patients served at The George Washington University hospital.

Institution
MUSC
Recruitment Contact
Olivia Eilers
(843) 792-0979
eilerso@musc.edu

Evaluating Contributors to Relapse in Comorbid Major Depressive Disorder and Cannabis Use Disorder

Date Added
May 3rd, 2022
PRO Number
Pro00119957
Researcher
Erin Martin

List of Studies

Keywords
Depression, Substance Use
Summary

Both withdrawal symptoms and external stressors can contribute to relapse in people that are trying to quit using marijuana. These negative feelings may be more severe in people that also have Major Depressive Disorder, making it especially hard for them to quit. The purpose of this study is to examine differences in withdrawal symptoms and stress response in people with Cannabis Use Disorder that do or do not also have major depression. Study participation will involve 3 on-site laboratory visits over 6 days. Participants will be asked to not use marijuana for 3 of those days. Participants will complete mobile phone surveys multiple times each day, wear a watch to assess sleep quality, and provide blood samples for testing at each laboratory visit. At the final laboratory visit, participants will complete a stress task.

Institution
MUSC
Recruitment Contact
Erin Martin
843-876-3528
marterin@musc.edu



-- OR --